NANOBIOTIX (EPA:NANO) | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Home
Companies
NANOBIOTIX

BRIEF

published on 10/31/2024 at 08:35, 21 days 4 hours ago

NANOBIOTIX participera aux conférences investisseurs en novembre

Innovation Conférences Investisseurs Soins De Santé NANOBIOTIX
BRIEF

published on 10/31/2024 at 08:35, 21 days 4 hours ago

NANOBIOTIX to Participate in Investor Conferences in November

Innovation Investors Healthcare Conférences NANOBIOTIX
PRESS RELEASE

published on 10/31/2024 at 08:30, 21 days 4 hours ago

NANOBIOTIX to Participate in Multiple Investor Conferences in November
Nanobiotix to participate in multiple investor conferences in November, including Guggenheim, Stifel, and Jefferies events to discuss innovative healthcare approaches

Investor Conferences Healthcare Innovation NANOBIOTIX Nanoparticle-based Approaches Late-stage Biotechnology
BRIEF

published on 10/11/2024 at 22:20, 1 month 9 days ago

Voting Rights and Share Capital Update by Nanobiotix

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF

published on 10/11/2024 at 22:20, 1 month 9 days ago

Mise à jour des droits de vote et du capital social par Nanobiotix

Euronext Paris Capital Social Nasdaq Droit De Vote NANOBIOTIX
PRESS RELEASE

published on 10/11/2024 at 22:15, 1 month 9 days ago

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Nanobiotix publie mensuellement le nombre total d'actions et de droits de vote. La société de biotechnologie développe des traitements innovants. Pour plus d'informations, visitez www.nanobiotix.com

Droits De Vote Biotechnologie Actions Traitements NANOBIOTIX
PRESS RELEASE

published on 10/11/2024 at 22:15, 1 month 9 days ago

Voting Rights and Shares Capital of the Company
Nanobiotix discloses voting rights and shares capital information. Find out more about the company's innovative therapeutic approaches

Voting Rights Biotechnology Shares Capital NANOBIOTIX Therapeutic Approaches
PRESS RELEASE

published on 09/18/2024 at 22:42, 2 months 2 days ago

Rapport Financier Semestriel 2024
BRIEF

published on 09/18/2024 at 22:20, 2 months 2 days ago

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

Revenue Increase Clinical Milestones Nanobiotix Financials NBTXR3 Progress Cash And Runway
BRIEF

published on 09/18/2024 at 22:20, 2 months 2 days ago

NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers du premier semestre 2024

Augmentation Des Revenus Résultats Financiers De Nanobiotix Progression De NBTXR3 Étapes Cliniques Marquantes De L'argent Et De La Piste

1 2 ... 6

Accesswire

Published on 11/21/2024 at 12:00, 46 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 46 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 16 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 43 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 46 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 11 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 31 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 40 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 46 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 16 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 5 hours 48 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 48 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 48 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 39 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 26 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE